The evolution of treatment for early breast cancer: what's next?

T Howell¹

Affiliations

¹ Cancer Research Campaign Department of Medical Oncology, University of Manchester, Christie Hospital and Holt Radium Institute, Wilmslow Road, Manchester, M20 4BX, UK.

T Howell. Ecancermedicalscience. 2009.

. 2009:3:148.

doi: 10.3332/ecancer.2009.148. Epub 2009 Jun 9.

T Howell¹

¹ Cancer Research Campaign Department of Medical Oncology, University of Manchester, Christie Hospital and Holt Radium Institute, Wilmslow Road, Manchester, M20 4BX, UK.

No abstract available

References

1. Saphner T, Tormey DC, et al. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738–46. - PubMed
1. Nolvadex Adjuvant Trial Organisation Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. 1983;321(8319):257–61. doi: 10.1016/S0140-6736(83)91683-5. - DOI - PubMed
1. Schteingart DE, Cash R, et al. Amino-glutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing’s syndrome. JAMA. 1966;198(9):1007–10. doi: 10.1001/jama.198.9.1007. - DOI - PubMed
1. Forbes J, on behalf on the ATAC Trialist’s Group ATAC: 100 month median follow-up shows continued superior efficacy and no excess fracture risk for anastrozole compared with tamoxifen after treatment completion. Lancet Oncol. 2008;9(1):45–53. 10.1016/S1470-2045(07)70385-6. - PubMed
1. Breast International Group (BIG) 1–98 Collaborative Group. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med. 2005;353:2747–57. - PubMed